137 related articles for article (PubMed ID: 28472350)
21. Activated protein C resistance and factor V Leiden: a review.
Rosendorff A; Dorfman DM
Arch Pathol Lab Med; 2007 Jun; 131(6):866-71. PubMed ID: 17550313
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
[TBL] [Abstract][Full Text] [Related]
23. Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy.
Dargaud Y; Trzeciak MC; Meunier S; Angei C; Pellechia D; Négrier C; Vinciguerra C
Br J Haematol; 2003 Oct; 123(2):342-5. PubMed ID: 14531918
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of factor V Leiden mutation testing in clinical practice.
Blinkenberg EØ; Kristoffersen AH; Sandberg S; Steen VM; Houge G
Eur J Hum Genet; 2010 Aug; 18(8):862-6. PubMed ID: 20332812
[TBL] [Abstract][Full Text] [Related]
25. Lupus anticoagulant interference in activated protein C resistance testing: in vitro phenomenon or in vivo pathophysiologic effect?
Shen YM; Cimo ML; Bai Y; Frenkel E; Sarode R
Clin Appl Thromb Hemost; 2011; 17(6):E190-5. PubMed ID: 21406411
[TBL] [Abstract][Full Text] [Related]
26. Implementation of a cost-effective unlabeled probe high-resolution melt assay for genotyping of Factor V Leiden.
Svensson AM; Chou LS; Meadows C; Miller CE; Palais R; Sumner K; Wayman TC; Mao R; Lyon E
Genet Test Mol Biomarkers; 2011 Apr; 15(4):207-13. PubMed ID: 21254846
[TBL] [Abstract][Full Text] [Related]
27. The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns.
Hyytiäinen S; Wartiovaara-Kautto U; Ulander VM; Kaaja R; Heikinheimo M; Petäjä J
Thromb Haemost; 2006 Mar; 95(3):434-40. PubMed ID: 16525570
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders.
Press RD; Bauer KA; Kujovich JL; Heit JA
Arch Pathol Lab Med; 2002 Nov; 126(11):1304-18. PubMed ID: 12421138
[TBL] [Abstract][Full Text] [Related]
29. [Diagnosis of thrombophilia based on coagulation and genetic studies].
Bałszan-Kowalska I
Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
[TBL] [Abstract][Full Text] [Related]
30. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
31. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
[TBL] [Abstract][Full Text] [Related]
32. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
Van Cott EM; Soderberg BL; Laposata M
Arch Pathol Lab Med; 2002 May; 126(5):577-82. PubMed ID: 11958664
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy.
Benten D; Widjaja A; von Depka M; Flemming P; Trautwein C; Böker K; Vogel A; Rosenau J; Manns MP
Z Gastroenterol; 2001 Oct; 39(10):837-40. PubMed ID: 11605152
[TBL] [Abstract][Full Text] [Related]
34. Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia.
Houghton DE; Sud S; Moll S; Rollins-Raval MA
Vasc Med; 2017 Dec; 22(6):527-528. PubMed ID: 28965480
[No Abstract] [Full Text] [Related]
35. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Paspatis GA; Sfyridaki A; Papanikolaou N; Triantafyllou K; Livadiotaki A; Kapsoritakis A; Lydataki N
Pathophysiol Haemost Thromb; 2002; 32(1):2-7. PubMed ID: 12214157
[TBL] [Abstract][Full Text] [Related]
36. Factor V Leiden and hepatic artery thrombosis after liver transplantation.
Dunn TB; Linden MA; Vercellotti GM; Gruessner RW
Clin Transplant; 2006; 20(1):132-5. PubMed ID: 16556168
[TBL] [Abstract][Full Text] [Related]
37. Laboratory Testing for Activated Protein C Resistance (APCR): An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():203-210. PubMed ID: 37204711
[TBL] [Abstract][Full Text] [Related]
38. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
Rolla R; Vidali M; Meola S; Pollarolo P; Pergolini P; Bellomo G
Clin Lab; 2011; 57(9-10):711-7. PubMed ID: 22029186
[TBL] [Abstract][Full Text] [Related]
39. Activated protein C (APC) resistance: considerations about the importance of using the original and modified methods in thrombophilic disease.
Gennari L; Blanco AN; Bermejo E; Salviú J; Grosso S; Lazzari MA
Thromb Haemost; 2000 Jul; 84(1):138-9. PubMed ID: 10928486
[No Abstract] [Full Text] [Related]
40. Increased sperm count may account for high population frequency of factor V Leiden.
Cohn DM; Repping S; Büller HR; Meijers JC; Middeldorp S
J Thromb Haemost; 2010 Mar; 8(3):513-6. PubMed ID: 20002540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
